Insights from Brain’s Waste-Flushing System May Improve Diagnosis of Idiopathic Intracranial Hypertension
MRI analysis that measures the activity of the glymphatic system may offer a noninvasive method for diagnosing unexplained brain pressure.
Press Release5 Minute ReadDec | 16 | 2020
Timothy Churchill, MDWe also found that athletes of both sexes frequently exceeded the general-population-defined normal values for a number of important measures of heart size.
BOSTON – Clinicians are often asked to assess competitive athletes with cardiovascular symptoms and to screen asymptomatic athletes for hidden heart problems. This is especially common with soccer, the world’s most popular sport. To provide guidance, a team led by investigators at Massachusetts General Hospital (MGH) conducted a study to determine what should be considered normal heart scan results in elite female and male soccer players. The findings are published in JAMA Cardiology.
When evaluating athletes, it’s important for physicians to differentiate between normal exercise-induced cardiovascular adaptations and abnormal responses that are detrimental to health. Knowing the difference requires analyses of sport- and sex-specific data. To this end, researchers examined cardiovascular data from 122 female and 116 male athletes from screenings overseen by Aaron Baggish, MD, director of the Cardiovascular Performance Program at MGH and chief cardiologist for U.S. Soccer, at U.S. Soccer National Team training locations from 2015 through 2019.
The screenings included both electrocardiograms, which assess the heart’s electrical activity, and echocardiograms (heart ultrasound), which show the heart’s structure. “Electrocardiograms that met international criteria for being abnormal were more common in the female athletes, but none of these individuals had evidence of underlying abnormalities on their heart ultrasounds,” says lead author Timothy Churchill, MD, an investigator in Medicine at MGH. “We also found that athletes of both sexes frequently exceeded the general-population-defined normal values for a number of important measures of heart size, likely reflective of the athletes’ hearts adapting to their exercise training.” Churchill stressed that none of the athletes had very worrisome findings or signs of heart muscle disease that would restrict them from competition.
The investigators hope that their study will provide clinicians with a reference that can be used when assessing athletes who are seen for either pre-participation screening or evaluation of heart-related symptoms. “These types of assessments arise frequently and are expected to become even more common as athletes return to competition in the setting of COVID-19 exposure or infection, given concerns that have emerged for potential cardiac involvement,” says Baggish, who was senior author of the study. “We hope our data can contextualize the athletes’ cardiac findings and help clinicians determine what is normal and what may suggest possible underlying disease.”
Funding
Support for the study came from MGH’s Cardiovascular Performance Program.
About the Massachusetts General Hospital
Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The Mass General Research Institute conducts the largest hospital-based research program in the nation, with annual research operations of more than $1 billion and comprises more than 9,500 researchers working across more than 30 institutes, centers and departments. In August 2020, Mass General was named #6 in the U.S. News & World Report list of "America’s Best Hospitals."
MRI analysis that measures the activity of the glymphatic system may offer a noninvasive method for diagnosing unexplained brain pressure.
A new clinical trial by investigators from Mass General Brigham found that the wake-promoting drug solriamfetol (Sunosi) helped early morning shift workers with shift work disorder stay more alert.
A national clinical trial led by investigators at Mass General Brigham Cancer Institute has found that abemaciclib, an oral cancer drug, may slow tumor growth in patients with aggressive meningiomas that have specific genetic mutations.
Mass General Brigham-developed system achieved high accuracy in validation studies, prompting release on open source to enable further investigations.
A team led by investigators at the Mass General Brigham Cancer Institute has discovered that a particular marker on tumor cells circulating in the blood indicates whether a patient with lung cancer will experience a lasting response to a newly approved immunotherapy called tarlatamab.
A new study by Mass General Brigham investigators identifies mutations that drive clinical resistance to rezatapopt treatment.